サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1631129

胃食道逆流症治療の市場規模、シェア、動向分析レポート：薬剤タイプ別、地域別、セグメント別予測、2025年～2030年

Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Type, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
胃食道逆流症治療の市場規模、シェア、動向分析レポート：薬剤タイプ別、地域別、セグメント別予測、2025年～2030年
出版日: 2024年12月10日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

胃食道逆流症治療市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の胃食道逆流症（GERD）治療市場規模は2030年までに57億7,000万米ドルに達すると予測されています。

同市場は2025～2030年にかけてCAGR 2.0％で成長すると予測されています。この成長は、胃食道逆流症やその他の胃腸疾患の有病率の増加に起因しています。さらに、ライフスタイルや食習慣の変化、GERD管理機器に関連する成功率の低さ、セルフメディケーション需要の増加が産業の成長をさらに促進しています。

胃食道逆流やその他の胃疾患の有病率の増加が市場の成長を促進しています。例えば、全人口の約13.98%がGERDに罹患していると推定されており、これは世界全体で約10億3,000万人がGERDに苦しんでいることに相当します。罹患率の増加は、適切な治療の必要性を後押ししています。未確認の問題を治療するために市販薬を使用している人は、そのリスクが高い可能性があります。未治療のGERDは不快感を増大させるだけでなく、さらなる医療的問題を引き起こす可能性があります。

GERDの治療には一般的に生活習慣の改善、外科的治療、内科的治療が含まれます。生活習慣の改善に反応しない患者には治療的介入が行われます。制酸薬、PPIやヒスタミン（H2）受容体拮抗薬（H2RA）のような分泌抑制薬、運動促進薬などが治療として用いられます。ファモチジンとシメチジンは米国食品医薬品局（FDA）の認可を受けた2つのH2RAであり、現在米国では市販されています。その他のH2RAで使用頻度の高いラニチジンは、有効成分に予期せぬ不純物が含まれていたため、潜在的な健康リスクや安全性の懸念から回収されています。

さらに、主要企業は胃食道逆流症治療の取り込みに注力しています。例えば、2022年5月、Phathom Pharmaceuticalsは、VonoprazanのFDA承認を発表しました。Vonoprazanは、すべてのグレードのびらん性食道炎を有する成人の治療であり、胸焼けの治癒と緩和を目的としています。さらに、JBファーマは2022年11月、酸逆流や胸やけを素早く緩和する新規製剤「ランラフト」を発売しました。

胃食道逆流症治療市場レポートハイライト

  • 制酸剤セグメントは2024年の胃食道逆流症治療市場を独占しており、制酸剤は胃内の酸に対抗する傾向があるため、迅速かつ短時間で症状を緩和することができます。
  • さらなる医療的問題につながる不必要な状態に起因する未治療の状態は、適切な治療の需要を推進しています。
  • 新興国市場で活動する主要参入企業は、GERDを通じて発生する不快な状態を抑制するのに役立つ薬の開発に注力しています。
  • 北米が最大の市場シェアを占めているが、これは障害を持つ患者のリハビリを促進する診断技術の技術的進歩が増加していることに起因しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 胃食道逆流症治療市場の変数、動向、範囲

  • 市場系統の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 産業分析-ポーターのファイブフォース分析
    • PESTLE分析

第4章 胃食道逆流症治療市場：薬剤タイプ別ビジネス分析

  • 薬剤タイプ別市場シェア、2024年と2030年
  • 薬剤タイプセグメントダッシュボード
  • 市場規模と予測と動向分析、医薬品タイプ別、2018～2030年
  • 制酸剤
  • H2受容体遮断薬
  • プロトンポンプ阻害剤（PPI）
  • 運動促進剤

第5章 胃食道逆流症治療市場：地域別、推定・動向分析

  • 地域別市場シェア分析、2024年と2030年
  • 地域別市場ダッシュボード
  • 市場規模、予測動向分析、2018～2030年
  • 北米
    • 国別、2018～2030年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 国別、2018～2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • デンマーク
    • スウェーデン
  • アジア太平洋
    • 国別、2018～2030年
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • 国別、2018～2030年
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 国別、2018～2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第6章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • AstraZeneca
    • Eisai Co., Ltd.
    • GSK plc.
    • Takeda Pharmaceutical Company Limited
    • Ironwood
    • Johnson & Johnson Services, Inc.
    • SFJ Pharmaceuticals
    • Sebela Pharmaceuticals
    • Phathom Pharmaceuticals, Inc.
    • Camber Pharmaceuticals, Inc.
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global gastroesophageal reflux disease therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 5 North America gastroesophageal reflux disease therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 6 North America gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 7 U.S. gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 8 Canada gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 9 Mexico gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 10 Europe gastroesophageal reflux disease therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 11 Europe gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 12 UK gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 13 Germany gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 14 France gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 15 Italy gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 16 Spain gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 17 Norway gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 18 Denmark gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 19 Sweden gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 20 Asia Pacific gastroesophageal reflux disease therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 21 Asia Pacific gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 22 Japan gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 23 China gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 24 India gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 25 Australia gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 26 South Korea gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 27 Thailand gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 28 Latin America gastroesophageal reflux disease therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 29 Latin America gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 30 Brazil gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 31 Argentina gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 32 Middle East & Africa Gastroesophageal reflux disease therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 33 Middle East & Africa gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 34 South Africa gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 35 Saudi Arabia gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 36 UAE gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 37 Kuwait gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Gastroesophageal reflux disease therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Drug type outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Gastroesophageal reflux disease therapeutics market dynamics
  • Fig. 12 Gastroesophageal reflux disease therapeutics market: Porter's five forces analysis
  • Fig. 13 Gastroesophageal reflux disease therapeutics market: PESTLE analysis
  • Fig. 14 Gastroesophageal reflux disease therapeutics market: Drug type segment dashboard
  • Fig. 15 Gastroesophageal reflux disease therapeutics market: Drug type market share analysis, 2024 & 2030
  • Fig. 16 Antacids market, 2018 - 2030 (USD Million)
  • Fig. 17 H2 receptor blockers market, 2018 - 2030 (USD Million)
  • Fig. 18 Proton pump inhibitors (PPIs) market, 2018 - 2030 (USD Million)
  • Fig. 19 Pro-kinetic agents market, 2018 - 2030 (USD Million)
  • Fig. 20 Gastroesophageal reflux disease therapeutics market revenue, by region
  • Fig. 21 Regional marketplace: Key takeaways
  • Fig. 22 Regional marketplace: Key takeaways
  • Fig. 23 North America gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. country dynamics
  • Fig. 25 U.S. gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 26 Canada country dynamics
  • Fig. 27 Canada gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 28 Mexico country dynamics
  • Fig. 29 Mexico gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 30 Europe gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 31 UK country dynamics
  • Fig. 32 UK gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 33 Germany country dynamics
  • Fig. 34 Germany gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 35 France country dynamics
  • Fig. 36 France gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 37 Italy country dynamics
  • Fig. 38 Italy gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 39 Spain country dynamics
  • Fig. 40 Spain gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 41 Norway country dynamics
  • Fig. 42 Norway gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 43 Sweden country dynamics
  • Fig. 44 Sweden gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark country dynamics
  • Fig. 46 Denmark gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 48 Japan country dynamics
  • Fig. 49 Japan gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 50 China country dynamics
  • Fig. 51 China gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 52 India country dynamics
  • Fig. 53 India gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 54 Australia country dynamics
  • Fig. 55 Australia gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 56 South Korea country dynamics
  • Fig. 57 South Korea gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 58 Thailand country dynamics
  • Fig. 59 Thailand gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 60 Latin America gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 61 Brazil country dynamics
  • Fig. 62 Brazil gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 63 Argentina country dynamics
  • Fig. 64 Argentina gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 65 MEA gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 66 South Africa country dynamics
  • Fig. 67 South Africa gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 68 Saudi Arabia country dynamics
  • Fig. 69 Saudi Arabia gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 70 UAE country dynamics
  • Fig. 71 UAE gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 72 Kuwait country dynamics
  • Fig. 73 Kuwait gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 74 Company categorization
  • Fig. 75 Company market position analysis
  • Fig. 76 Strategic framework
目次
Product Code: GVR-1-68038-778-0

Gastroesophageal Reflux Disease Therapeutics Market Growth & Trends:

The global gastroesophageal reflux disease therapeutics market size is anticipated to reach USD 5.77 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 2.0% from 2025 to 2030. The growth is attributed to increasing prevalence of gastroesophageal reflux disease and other gastrointestinal diseases. Moreover, change in lifestyle and food habits, low success rates associated with GERD management devices and increasing demand for self-medication is further propelling the industry growth.

Increasing prevalence of gastroesophageal reflux and other gastric disorders is propelling the growth of the market. For instance, it is estimated that around 13.98% of total population is affected by GERD, which equals to around 1.03 billion people suffering from GERD globally. The rising incidence of the condition propels the need for proper treatment. Individuals using over-the-counter medication to treat unidentified problems may be at a higher risk. Untreated GERD condition not only increases uncomfortableness but may result in a number of additional medical issues.

Treatment of GERD generally includes lifestyle modification, surgical therapy, and medical therapy. Patients who do not respond to lifestyle changes receive a therapeutic intervention. Antacids, antisecretory drugs like PPI treatment or histamine (H2) receptor antagonists (H2RAs), and prokinetic drugs make up therapeutics. Famotidine and cimetidine are two H2RAs that have been licensed by the US Food and Drug Administration (FDA) and are currently offered over the counter in the US. Because of an unanticipated impurity in the active ingredient, the other H2RA that is frequently used, ranitidine, has been recalled due to a potential health risk or safety concern.

Furthermore, key players are focusing on incorporating gastroesophageal reflux disease therapeutics. For instance, in May 2022, Phathom Pharmaceuticals announced FDA approval for Vonoprazan, a NDA for the treatment of adults with all grades of erosive esophagitis and to provide healing and relief from heartburn. Moreover, in November 2022, JB Pharma launched RANRAFT, a novel formulation that helps in providing quick relief for acid reflux and heartburn.

Gastroesophageal Reflux Disease Therapeutics Market Report Highlights:

  • Antacids segment dominated the gastroesophageal reflux disease treatment market in 2024 and is attributable to the rapid and quick relief offered by antacids, as they tend to counteract the acidity inside the stomach.
  • Untreated condition owing to unnecessary condition that leads to additional medical issues is propelling the demand for proper therapeutics.
  • Key players operating in the market are focusing on developing medications that helps in curbing the uncomfortable condition occurring through GERD.
  • North America held the largest market share which can be attributed to the increasing technological advancements in diagnostics technologies that facilitate rehabilitation of disabled patients.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Type
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Gastroesophageal Reflux Disease Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Gastroesophageal Reflux Disease Therapeutics Market: Drug Type Business Analysis

  • 4.1. Drug Type Market Share, 2024 & 2030
  • 4.2. Drug Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
  • 4.4. Antacids
    • 4.4.1. Antacids Market, 2018 - 2030 (USD Million)
  • 4.5. H2 Receptor Blockers
    • 4.5.1. H2 Receptor Blockers Market, 2018 - 2030 (USD Million)
  • 4.6. Proton Pump Inhibitors (PPIs)
    • 4.6.1. Proton Pump Inhibitors (PPIs) Market, 2018 - 2030 (USD Million)
  • 4.7. Pro-kinetic Agents
    • 4.7.1. Pro-kinetic Agents Market, 2018 - 2030 (USD Million)

Chapter 5. Gastroesophageal Reflux Disease Therapeutics Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Share Analysis, 2024 & 2030
  • 5.2. Regional Market Dashboard
  • 5.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 5.4. North America
    • 5.4.1. North America Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 5.4.2. U.S.
      • 5.4.2.1. Key Country Dynamics
      • 5.4.2.2. Regulatory Framework
      • 5.4.2.3. Competitive Insights
      • 5.4.2.4. U.S. Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Canada
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Regulatory Framework
      • 5.4.3.3. Competitive Insights
      • 5.4.3.4. Canada Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. Mexico
      • 5.4.4.1. Key Country Dynamics
      • 5.4.4.2. Regulatory Framework
      • 5.4.4.3. Competitive Insights
      • 5.4.4.4. Mexico Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Europe
    • 5.5.1. Europe Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 5.5.2. UK
      • 5.5.2.1. Key Country Dynamics
      • 5.5.2.2. Regulatory Framework
      • 5.5.2.3. Competitive Insights
      • 5.5.2.4. UK Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.5.3. Germany
      • 5.5.3.1. Key Country Dynamics
      • 5.5.3.2. Regulatory Framework
      • 5.5.3.3. Competitive Insights
      • 5.5.3.4. Germany Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.5.4. France
      • 5.5.4.1. Key Country Dynamics
      • 5.5.4.2. Regulatory Framework
      • 5.5.4.3. Competitive Insights
      • 5.5.4.4. France Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.5.5. Italy
      • 5.5.5.1. Key Country Dynamics
      • 5.5.5.2. Regulatory Framework
      • 5.5.5.3. Competitive Insights
      • 5.5.5.4. Italy Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.5.6. Spain
      • 5.5.6.1. Key Country Dynamics
      • 5.5.6.2. Regulatory Framework
      • 5.5.6.3. Competitive Insights
      • 5.5.6.4. Spain Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.5.7. Norway
      • 5.5.7.1. Key Country Dynamics
      • 5.5.7.2. Regulatory Framework
      • 5.5.7.3. Competitive Insights
      • 5.5.7.4. Norway Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.5.8. Denmark
      • 5.5.8.1. Key Country Dynamics
      • 5.5.8.2. Regulatory Framework
      • 5.5.8.3. Competitive Insights
      • 5.5.8.4. Denmark Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.5.9. Sweden
      • 5.5.9.1. Key Country Dynamics
      • 5.5.9.2. Regulatory Framework
      • 5.5.9.3. Competitive Insights
      • 5.5.9.4. Sweden Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Asia Pacific
    • 5.6.1. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 5.6.2. Japan
      • 5.6.2.1. Key Country Dynamics
      • 5.6.2.2. Regulatory Framework
      • 5.6.2.3. Competitive Insights
      • 5.6.2.4. Japan Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.6.3. China
      • 5.6.3.1. Key Country Dynamics
      • 5.6.3.2. Regulatory Framework
      • 5.6.3.3. Competitive Insights
      • 5.6.3.4. China Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.6.4. India
      • 5.6.4.1. Key Country Dynamics
      • 5.6.4.2. Regulatory Framework
      • 5.6.4.3. Competitive Insights
      • 5.6.4.4. India Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.6.5. South Korea
      • 5.6.5.1. Key Country Dynamics
      • 5.6.5.2. Regulatory Framework
      • 5.6.5.3. Competitive Insights
      • 5.6.5.4. South Korea Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.6.6. Australia
      • 5.6.6.1. Key Country Dynamics
      • 5.6.6.2. Regulatory Framework
      • 5.6.6.3. Competitive Insights
      • 5.6.6.4. Australia Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.6.7. Thailand
      • 5.6.7.1. Key Country Dynamics
      • 5.6.7.2. Regulatory Framework
      • 5.6.7.3. Competitive Insights
      • 5.6.7.4. Thailand Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Latin America
    • 5.7.1. Latin America Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 5.7.2. Brazil
      • 5.7.2.1. Key Country Dynamics
      • 5.7.2.2. Regulatory Framework
      • 5.7.2.3. Competitive Insights
      • 5.7.2.4. Brazil Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.7.3. Argentina
      • 5.7.3.1. Key Country Dynamics
      • 5.7.3.2. Regulatory Framework
      • 5.7.3.3. Competitive Insights
      • 5.7.3.4. Argentina Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.8. MEA
    • 5.8.1. MEA Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 5.8.2. South Africa
      • 5.8.2.1. Key Country Dynamics
      • 5.8.2.2. Regulatory Framework
      • 5.8.2.3. Competitive Insights
      • 5.8.2.4. South Africa Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.8.3. Saudi Arabia
      • 5.8.3.1. Key Country Dynamics
      • 5.8.3.2. Regulatory Framework
      • 5.8.3.3. Competitive Insights
      • 5.8.3.4. Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.8.4. UAE
      • 5.8.4.1. Key Country Dynamics
      • 5.8.4.2. Regulatory Framework
      • 5.8.4.3. Competitive Insights
      • 5.8.4.4. UAE Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.8.5. Kuwait
      • 5.8.5.1. Key Country Dynamics
      • 5.8.5.2. Regulatory Framework
      • 5.8.5.3. Competitive Insights
      • 5.8.5.4. Kuwait Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Participant Overview
  • 6.2. Company Market Position Analysis
  • 6.3. Company Categorization
  • 6.4. Strategy Mapping
  • 6.5. Company Profiles/Listing
    • 6.5.1. AstraZeneca
      • 6.5.1.1. Overview
      • 6.5.1.2. Financial Performance
      • 6.5.1.3. Product Benchmarking
      • 6.5.1.4. Strategic Initiatives
    • 6.5.2. Eisai Co., Ltd.
      • 6.5.2.1. Overview
      • 6.5.2.2. Financial Performance
      • 6.5.2.3. Product Benchmarking
      • 6.5.2.4. Strategic Initiatives
    • 6.5.3. GSK plc.
      • 6.5.3.1. Overview
      • 6.5.3.2. Financial Performance
      • 6.5.3.3. Product Benchmarking
      • 6.5.3.4. Strategic Initiatives
    • 6.5.4. Takeda Pharmaceutical Company Limited
      • 6.5.4.1. Overview
      • 6.5.4.2. Financial Performance
      • 6.5.4.3. Product Benchmarking
      • 6.5.4.4. Strategic Initiatives
    • 6.5.5. Ironwood
      • 6.5.5.1. Overview
      • 6.5.5.2. Financial Performance
      • 6.5.5.3. Product Benchmarking
      • 6.5.5.4. Strategic Initiatives
    • 6.5.6. Johnson & Johnson Services, Inc.
      • 6.5.6.1. Overview
      • 6.5.6.2. Financial Performance
      • 6.5.6.3. Product Benchmarking
      • 6.5.6.4. Strategic Initiatives
    • 6.5.7. SFJ Pharmaceuticals
      • 6.5.7.1. Overview
      • 6.5.7.2. Financial Performance
      • 6.5.7.3. Product Benchmarking
      • 6.5.7.4. Strategic Initiatives
    • 6.5.8. Sebela Pharmaceuticals
      • 6.5.8.1. Overview
      • 6.5.8.2. Financial Performance
      • 6.5.8.3. Product Benchmarking
      • 6.5.8.4. Strategic Initiatives
    • 6.5.9. Phathom Pharmaceuticals, Inc.
      • 6.5.9.1. Overview
      • 6.5.9.2. Financial Performance
      • 6.5.9.3. Product Benchmarking
      • 6.5.9.4. Strategic Initiatives
    • 6.5.10. Camber Pharmaceuticals, Inc.
      • 6.5.10.1. Overview
      • 6.5.10.2. Financial Performance
      • 6.5.10.3. Product Benchmarking
      • 6.5.10.4. Strategic Initiatives